Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
In this patient perspective find out T.J.’s viewpoint on the potentially practice-changing lung cancer findings presented at the AACR 2018.
Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
Discover details of the KEYNOTE-045, which recently resulted in the recommendation for the use of pembrolizumab within the cancer drugs fund as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
Discover the case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatments and demonstrated a striking response to pembrolizumab.
Patients with cancerous forms of gestational trophoblastic disease went into remission after treatment with pembrolizumab.
In this interview with James Gulley find out about Phase I clinical trial for M7824 (a bifunctional fusion protein immunotherapy that targets both PD-L1 and TGF-beta), which has demonstrated preliminary effectiveness in patients with advanced solid tumors.